PHAT Phathom Pharmaceuticals

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Jonathan Bentley as Senior Vice President, Head of Sales, the Company’s Board of Directors has approved the grant of inducement awards.

On May 1, 2025, the Company’s Board of Directors granted inducement awards to Mr. Bentley under the Company’s 2025 Employment Inducement Incentive Award Plan (the “Inducement Plan”). Mr. Bentley was granted a non-qualified stock option to purchase 79,365 shares of Phathom common stock under the Inducement Plan, 25% of which will vest on May 1, 2026, and the remainder of which will vest in 36 equal monthly installments thereafter. The stock option has an exercise price equal to the closing price of Phathom’s common stock on the Nasdaq Global Select Market on the grant date. In addition, Mr. Bentley was granted an award of 57,143 restricted stock units, one-third of which will vest in three equal annual installments, and an award of 50,000 restricted stock units, which will vest in two equal annual installments. The vesting of all awards is subject to continued service. The awards will be subject to the terms and conditions of the Inducement Plan and the applicable award agreements. The awards are being granted as an inducement material to Mr. Bentley entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

About Phathom Pharmaceuticals, Inc.



Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at  follow on  and .

MEDIA CONTACT

Nick Benedetto

1-877-742-8466

INVESTOR CONTACT

Eric Sciorilli

1-877-742-8466

© 2025 Phathom Pharmaceuticals. All rights reserved.

VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.



EN
01/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Phathom Pharmaceuticals

 PRESS RELEASE

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listi...

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Jonathan Bentley as Senior Vice President, Head of Sales, the Company’s Board of Directors has approved the grant of inducement awards. On May 1, 2025, the Company’s Board of Directors granted inducement awards to Mr. Bentl...

 PRESS RELEASE

Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results a...

Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update VOQUEZNA launch momentum continues with over 390,000 prescriptions filled to date, written by more than 23,600 healthcare providersNet revenues of $28.5 million reported for Q1Filled VOQUEZNA prescriptions increased ~8% in Q1 over the prior quarter despite seasonal headwindsStrategic cost reductions and executive leadership changes implemented to support sustainable revenue growth and achieve profit from operations, excluding stock-based compensation, in 2026Management to host conference call t...

 PRESS RELEASE

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW ...

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting New data includes real-world analyses of VOQUEZNA-treated patients in the U.S. diagnosed with gastroesophageal reflux disease (GERD) FLORHAM PARK, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that the company will present real-world data for its first-in-class treatment VOQUEZNA® (vonoprazan) at Digestive Disease Week® (D...

 PRESS RELEASE

Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results...

Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025 • Management to host conference call on Thursday, May 1, 2025, at 8:00 am EDT FLORHAM PARK, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a business update. ...

 PRESS RELEASE

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directo...

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors FLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Ted Schroeder to its Board of Directors. Mr. Schroeder brings more than three decades of experience leading innovative biopharmaceutical companies and has a strong track record of building and scaling commercial organizations, bringing new therapies to market, and su...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch